Wellgistics Health (WGRX) announced the termination of its equity purchase agreement with Hudson Global Ventures. The ELOC was an effective tool that nearly doubled the Company’s original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation. Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGRX:
- Wellgistics Health launches XRP Payment Program for independent pharmacies
- Wellgistics Health Inc Announces Debt-to-Equity Conversion
- Wellgistics Health converts $8.1M debt to equity
- Wellgistics Health files to sell common stock, warrants, no amount given
- Wellgistics Health accelerates platform growth in Q2